GlassScriptPhysician profile
Ashish A Correa
NPI 1780091553
$13,542.71
in general payments reported to CMS, 2019-2025
31 companies · $1,394 in 2025
The $1,394 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2020: $1,183 · 2021: $2,069 · 2022: $2,672 · 2023: $2,744 · 2024: $3,345 · 2025: $1,394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,586 · Travel and Lodging: $897.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,586.20 |
| Travel and Lodging | $896.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $6,420.21 | 2020-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Amgen INC. | $1,050.16 | 2020-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $1,013.36 | 2020-2025 | Farxiga, Wainua, Lokelma |
| Cvrx, INC. | $809.79 | 2022-2025 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $645.11 | 2021-2023 | Jardiance |
| Abiomed | $431.80 | 2020-2024 | Impella |
| Novo Nordisk INC | $405.71 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Alnylam Pharmaceuticals INC. | $368.05 | 2022-2025 | Onpattro, Amvuttra |
| Novartis Pharmaceuticals Corporation | $310.26 | 2022-2025 | |
| Boston Scientific Corporation | $268.82 | 2020-2021 | |
| Heartflow, INC. | $206.87 | 2025 | |
| Pfizer INC. | $198.61 | 2019-2023 | |
| Ancora Heart, INC. | $197.55 | 2023 | Accucinch |
| Merck Sharp & Dohme LLC | $174.01 | 2022-2023 | Verquvo |
| Paragonix Technologies, INC. | $160.04 | 2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $140.87 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $128.05 | 2022-2023 | Camzyos |
| Esperion Therapeutics, INC. | $125.00 | 2021 | |
| Cardiovascular Systems INC. | $116.38 | 2021 | |
| Scpharmaceuticals INC. | $83.93 | 2023-2024 | |
| Astellas Pharma US INC | $79.99 | 2021 | |
| Lantheus Medical Imaging, INC. | $43.03 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $39.54 | 2023 | Inpefa |
| Philips North America LLC | $29.76 | 2024 | (Br3) Coronary Other |
| Cmp Pharma, INC. | $24.78 | 2022 | |
| Daiichi Sankyo INC. | $20.72 | 2022 | |
| Lilly USA, LLC | $20.30 | 2023 | Mounjaro |
| Medtronic, INC. | $18.87 | 2021 | |
| Akcea Therapeutics, INC. | $11.14 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashish Correa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.